Genitourinary Cancers

David I. Quinn, PhD, MBBS, discusses the molecular diagnosis of renal cell carcinoma and also highlights emerging therapies in the treatment of patients with different subtypes of prostate cancer.

Robert Dreicer, MD, professor of medicine and urology, University of Virginia Health System, section chief, Medical Oncology, deputy director, UVA Cancer Center, discusses biomarkers of response to immunotherapy in patients with metastatic urothelial cancer.

Paul R. Eber, MD, a urologist at Conrad-Pearson Clinic, discusses takeaways from the CARMENA trial in metastatic renal cell carcinoma (mRCC).

Jonathan L. Wright, MD, MS, FACS, medical director of the University of Washington Medical Center Urology Clinic, associate professor of urology at University of Washington, and affiliate investigator at the Fred Hutchinson Cancer Research Center, discusses frontline considerations in patients with locally advanced, muscle-invasive bladder cancer.

Brian M. Shuch, MD, director, Kidney Cancer Program, Alvin & Carrie Meinhardt Endowed Chair of Kidney Cancer Research, University of California, Los Angeles Institute of Urologic Oncology, discusses patient factors to take into consideration when deciding appropriate treatment for patients with advanced renal cell carcinoma.

Currently, there is no reliable way to identify who can safely avoid radical cystectomy following MIBC treatment. For this reason, Fox Chase Cancer Center researchers are trying to find the as-yet-elusive 30% by asking 3 important questions.

Enfortumab vedotin showed strong clinical activity in patients with locally advanced or metastatic urothelial carcinoma who previously received both platinum-containing chemotherapy and immune checkpoint therapy, according to topline results from the pivotal phase II EV-201 trial.

Bradley G. Somer, MD, an associate professor of hematology/oncology and head of strategic expansion/development at the University of Tennessee West Cancer Center, discusses optimal combinations for the treatment of patients with metastatic renal cell carcinoma (mRCC) in the frontline setting.

David I. Quinn, MBBS, PhD, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, USC Keck School of Medicine, discusses targetable molecular pathways in renal cell carcinoma.

Thomas W. Flaig, MD, discusses the latest updates to the NCCN guidelines for the treatment of patients with muscle-invasive bladder cancer and highlights the latest approvals of checkpoint inhibitors in this patient population.

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses unanswered questions with immunotherapy in the treatment of patients with renal cell carcinoma.

The 2019 National Comprehensive Cancer Network guideline on the management of advanced clear cell renal cell carcinoma undergoes a major shift in risk category used to define preferred and alternative first-line treatments.

Brian M. Shuch, MD, highlights the complex data with cytoreductive nephrectomy in renal cell carcinoma and offers advice on how to navigate the intricate treatment landscape.